LFA-1– and VLA-4–Mediated Adhesion of Leukemic Cells Derived From Both BM and Peripheral Blood
| Patient No. . | CD10+ (%) . | CD104-150 (mean) . | LFA-1 Adhesion4-151 . | VLA-4 Adhesion4-151 . | ||||
|---|---|---|---|---|---|---|---|---|
| Medium . | PMA . | KIM185 . | Medium . | PMA . | TS2/16 . | |||
| 2 | ||||||||
| BM | 94‡ | − | +/− | + | ++ | ++ | ++ | +++ |
| PB | 16 | + | − | − | − | − | − | +++ |
| 3 | ||||||||
| BM | 66 | ++ | +/− | + | ++ | ++ | ++ | +++ |
| PB | 61 | ++ | − | + | ++ | ++ | ++ | +++ |
| 5 | ||||||||
| BM | 73 | +++ | − | +/− | +++ | +++ | +++ | +++ |
| PB | 37 | +++ | − | − | ++ | ++ | ++ | +++ |
| 12 | ||||||||
| BM | 38 | +++ | − | − | ++ | ++ | +++ | +++ |
| PB | 69 | +++ | − | +/− | ++ | ++ | ++ | +++ |
| 17 | ||||||||
| BM | 100 | ++ | − | − | − | ++ | ++ | +++ |
| PB | 100 | ++ | − | − | − | ++ | ++ | +++ |
| 18 | ||||||||
| BM | 97‡ | − | − | − | − | + | ++ | ++ |
| PB | 10 | + | − | + | ++ | ++ | ++ | +++ |
| Patient No. . | CD10+ (%) . | CD104-150 (mean) . | LFA-1 Adhesion4-151 . | VLA-4 Adhesion4-151 . | ||||
|---|---|---|---|---|---|---|---|---|
| Medium . | PMA . | KIM185 . | Medium . | PMA . | TS2/16 . | |||
| 2 | ||||||||
| BM | 94‡ | − | +/− | + | ++ | ++ | ++ | +++ |
| PB | 16 | + | − | − | − | − | − | +++ |
| 3 | ||||||||
| BM | 66 | ++ | +/− | + | ++ | ++ | ++ | +++ |
| PB | 61 | ++ | − | + | ++ | ++ | ++ | +++ |
| 5 | ||||||||
| BM | 73 | +++ | − | +/− | +++ | +++ | +++ | +++ |
| PB | 37 | +++ | − | − | ++ | ++ | ++ | +++ |
| 12 | ||||||||
| BM | 38 | +++ | − | − | ++ | ++ | +++ | +++ |
| PB | 69 | +++ | − | +/− | ++ | ++ | ++ | +++ |
| 17 | ||||||||
| BM | 100 | ++ | − | − | − | ++ | ++ | +++ |
| PB | 100 | ++ | − | − | − | ++ | ++ | +++ |
| 18 | ||||||||
| BM | 97‡ | − | − | − | − | + | ++ | ++ |
| PB | 10 | + | − | + | ++ | ++ | ++ | +++ |